WEBULL
News
MGTX
8.65
+0.58%
0.05
Weekly Report: what happened at MGTX last week (1124-1128)?
Weekly Report · 6d ago
MeiraGTx Holdings Initiated at Buy by HC Wainwright & Co.
Dow Jones · 11/24 15:24
MeiraGTx Holdings Price Target Announced at $20.00/Share by HC Wainwright & Co.
Dow Jones · 11/24 15:24
HC Wainwright & Co. Initiates Coverage On MeiraGTx Hldgs with Buy Rating, Announces Price Target of $20
Benzinga · 11/24 15:14
MeiraGTx initiated with a Buy at H.C. Wainwright
TipRanks · 11/24 11:15
MEIRAGTX HOLDINGS PLC <MGTX.O>: H.C. WAINWRIGHT INITIATES COVERAGE WITH BUY RATING AND TARGET PRICE $20
Reuters · 11/24 11:11
Weekly Report: what happened at MGTX last week (1117-1121)?
Weekly Report · 11/24 09:15
U.S. RESEARCH ROUNDUP-Alignment Healthcare, BJ's Wholesale Club Holdings, Hyatt Hotels
Reuters · 11/24 08:05
MeiraGTx Holdings plc to Participate in Evercore HealthCONx Conference
Reuters · 11/20 20:00
Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference
PR Newswire · 11/20 20:00
Analysts Have Lowered Expectations For MeiraGTx Holdings plc (NASDAQ:MGTX) After Its Latest Results
Simply Wall St · 11/17 10:00
Weekly Report: what happened at MGTX last week (1110-1114)?
Weekly Report · 11/17 09:15
MeiraGTx Holdings Is Maintained at Outperform by RBC Capital
Dow Jones · 11/14 16:03
MeiraGTx Holdings Price Target Raised to $16.00/Share From $12.00 by RBC Capital
Dow Jones · 11/14 16:03
RBC Capital Maintains Outperform on MeiraGTx Hldgs, Raises Price Target to $16
Benzinga · 11/14 15:53
MeiraGTx Holdings Is Maintained at Buy by Chardan Capital
Dow Jones · 11/14 13:35
MeiraGTx Holdings Price Target Maintained With a $35.00/Share by Chardan Capital
Dow Jones · 11/14 13:35
Chardan Capital Maintains Buy on MeiraGTx Hldgs, Maintains $35 Price Target
Benzinga · 11/14 13:25
RBC Capital Keeps Their Buy Rating on Meiragtx Holdings (MGTX)
TipRanks · 11/14 12:07
Bank of America Securities Sticks to Its Buy Rating for Meiragtx Holdings (MGTX)
TipRanks · 11/14 11:16
More
Webull provides a variety of real-time MGTX stock news. You can receive the latest news about Meiragtx Holdings Plc through multiple platforms. This information may help you make smarter investment decisions.
About MGTX
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.